Objectif Breast Cancer is the most common cancer type and main cause of cancer related death in women worldwide. One in eight women in the EU and US will develop breast cancer in their lifetime. Breast-Conserving Surgery (BCS) also called lumpectomy is a standard of care for early breast cancer. Unlike mastectomy, in which the entire breast and lymph nodes are removed, lumpectomy involves only removal of the cancerous tissue and a margin of healthy tissue. Government initiatives to increase public awareness for early breast cancer detection are drastically increasing the number of patients eligible for BCS. Now, BCS is the most performed breast cancer surgery and accounts today for about 70% of all breast cancer surgeries. In counterpart, BCS brings about a risk for the patient to need to undergo an additional surgery in case that not all the cancerous tissue is removed. Re-operation rates (RoR) in BCS are evaluated at 30% on average. Re-operation in BCS is costly for hospitals (€20.000 per re-operation), inconvenient for patients and delays initiation of adjuvant therapies. There is a clinical need for improved intra-operative margin assessment (IMA) methods to assess breast cancer tumor specimen margins in real time in the operating room to decrease RoR. HistologTM Digital Solution allows surgeons real-time, accurate, affordable, whole margin breast tumor assessment through the highest resolution at cellular and subcellular level by using a user-friendly graphical interface supported by a differentiating Automating Reading CAD tool without the need of a pathologist. HistologTM Digital Solution is fully compatible with the gold standard post-operational H&E assessment since it does not destroy specimen and can be integrated with patient information systems. SamanTree Medical’s goal is to make of HistologTM Digital Solution the standard for IMA of breast cancer tumor margins, and decrease the RoR from the current 30% to less than 3%. Champ scientifique natural sciencescomputer and information sciencessoftwaremedical and health sciencesclinical medicinesurgerysurgical specialtiesnatural sciencesphysical sciencesopticsmicroscopymedical and health sciencesclinical medicineoncologybreast cancernatural sciencescomputer and information sciencesartificial intelligencemachine learningdeep learning Mots‑clés microscopy histopathology breast cancer lumpectomy Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Thème(s) EIC-SMEInst-2018-2020 - SME instrument Appel à propositions H2020-EIC-SMEInst-2018-2020 Voir d’autres projets de cet appel Sous appel H2020-SMEInst-2018-2020-2 Régime de financement SME-2 - SME instrument phase 2 Coordinateur SAMAN TREE MEDICAL SA Contribution nette de l'UE € 2 317 087,50 Adresse AVENUE DE PROVENCE 12 1007 Lausanne Suisse Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Schweiz/Suisse/Svizzera Région lémanique Vaud Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 3 310 125,00
